Clinical Trial Update: Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab [Phase 2]

View source ↗

Summary

Phase 2 trial of albumin-bound paclitaxel with cetuximab for recurrent or metastatic head and neck cancer; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Cetuximab (cetuximab)

Snippet

Sponsor: University of California, Irvine | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-01-12